AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 101 min read$RXST

RxSight (NASDAQ: RXST) COO swaps high-priced options for new $6.375 grants

RxSight's (RXST) COO exchanged higher-priced stock options for new options at $6.375 per share. The new options have various vesting schedules under the 2021 Equity Incentive Plan, with some vesting monthly over 48 months and others in 2027.

Original reporting
stocktitan.net
Published Sep 10, 2026, 1:38 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 3:48 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$RXST
Neutral
high confidence
Mentioned
$RXST
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$RXSTNeutralLow
01

Why it matters

The filing provides transparency on executive compensation but is unlikely to affect stock price materially.

02

Market read

Minor insider transaction with limited trading relevance.

03

What to watch

Potential future dilution from vesting schedule, but amounts are modest relative to float.

Relevance 4/10Novelty 4/10Timing: reported Sep 5 2026

Background

RxSight (NASDAQ:RXST) disclosed an insider option exchange by its COO, replacing higher‑priced options with $6.375 options under its 2021 Equity Incentive Plan.

Company-level read

Ticker impact

$RXSTNeutralHigh confidence
Context

COO Ilya Goldshleger exchanged higher‑priced options for new $6.375 options on Sep 5 2026, disclosed via a Form 4 filing.

Expected impact

minimal impact; no immediate price move expected

Evidence & confidence

Small insider option swap with no cash component; market typically views such restructurings as neutral.

Market effects

Sector

None; the transaction is company‑specific and does not affect the broader ophthalmic device sector.

Regional

None; limited to US microcap investors.

Global

Low; no global market implications.

Counterpoint

What could challenge this read

If the COO expects the stock to rise, the lower strike could signal confidence, but the market may still ignore it.

Key entities

  • company
    RxSight Inc.

    US‑listed ophthalmic device maker.

  • executive
    Ilya Goldshleger

    Chief Operating Officer of RxSight.

Read at source← All news

Related articles

SEP 9
$RXSTMedAI 8/10

RxSight at wells fargo healthcare conference: reset centers on LAL growth

RxSight (RXST) outlined a turnaround plan at the Wells Fargo Healthcare Conference, focusing on increasing use of its Light Adjustable Lens (LAL) among existing surgeons. The company acknowledged commercial execution issues, with stock down 38% YTD. It plans to double its U.S. sales force and highlighted a $200M upfront partnership with Alcon. Management expects a return to growth but did not provide 2027 guidance. Revenue was $127.6M, down 13% YoY, with $210M in cash.

investing.com3 min
AUG 17
$ALCMed

Adjustable precision vision post-cataract surgery

Alcon and RxSight announced a non-exclusive collaboration to develop adjustable presbyopia-correcting intraocular lenses. RxSight’s Light Adjustable Lens is described as FDA-approved and adjustable after surgery via non-invasive light treatments. Alcon will lead global commercialization, RxSight will handle development and manufacturing and receive royalties on net sales.

nzoptics.co.nz3 min
AUG 14
$RXSTMedAI 8/10

RxSight (RXST) Q2 2026 Earnings Call Transcript

RxSight (RXST) held its Q2 2026 earnings call. The company said it withdrew full-year 2026 guidance and will resume formal guidance in early 2027. Q2 total revenue was $33.7M, including $6.5M from an Alcon collaboration. Product sales were $27.2M, down 19% YoY, with a Q2 net loss of $12.1M.

yahoo.com6 min
AUG 5
$RXSTMedAI 8/10

RXSIGHT, INC. REPORTS SECOND QUARTER 2026 RESULTS AND PROVIDES UPDATE ON 2026 OUTLOOK

RxSight, Inc. (RXST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 RXSIGHT, INC. REPORTS SECOND QUARTER 2026 RESULTS AND PROVIDES UPDATE ON 2026 OUTLOOK Aliso Viejo, Calif. – August 5, 2026 – RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended June 30, 2026, and provided an update on its 2026 financia

SEC EDGAR 8-K6 min
AUG 1
$RXSTMed

RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer

RxSight, Inc. (NASDAQ: RXST) announced a leadership transition effective July 20, 2026. Aziz Mottiwala will become President and CEO, succeeding Ron Kurtz, M.D., who will remain Chief Medical Officer. Kurtz will also resign from the board, with Mottiwala appointed in his place. The company cited commercial and clinical continuity around its light adjustable lens technology.

hrtoday.in3 min
JUL 20
$RXSTMed

RxSight Lands Tarsus Commercial Leader as CEO

RxSight (Nasdaq: RXST) appointed Aziz Mottiwala as CEO on July 15, replacing Dr. Ron Kurtz, who becomes chief medical officer. Mottiwala previously served as Tarsus Pharmaceuticals’ chief commercial officer. RXST shares rose 7.2% to $5.63 after the news. The article cites RXST’s forecast cuts and a Bank of America price target cut to $6.50, plus an Alcon partnership with $60 million upfront and up to $140 million in milestones.

ocbj.com6 min